FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308733071> ?p ?o ?g. }

• W4308733071 abstract "ABSTRACT Introduction Neuroendocrine neoplasms are a form of tumor that develops from a variety of neuroendocrine cell types and is most commonly found in the gastrointestinal tract. As the blood from the GI tract drains into the liver, it frequently metastasizes there. Intraarterial therapies, such as bland transarterial embolisation, conventional transarterial chemoembolisation, drug-eluting beads transarterial chemoembolisation, and transarterial radioembolization with yttrium-90 are advanced methods for limiting the burden of neuroendocrine liver metastasis tumors. Currently, there is no study that compares all of these methods. Our goal is to compare the efficacy and harm of each of transarterial therapies for stage IV neuroendocrine neoplasms by conducting this systematic review and network meta-analysis. Methods and Analysis We will search electronic databases (MEDLINE, Cochrane, Embase, Scopus, ClinicalTrials.gov ) from their inception to November 2022 to find all studies that compare survival and clinical finding between any two of the following intraarterial interventions: bland transarterial embolisation, conventional transarterial chemoembolisation, drug-eluting beads transarterial chemoembolisation, and transarterial radioembolization, the latter with yttrium-90. We will include randomized controlled trials (RCT), cluster-RCTs, and observational studies. We will investigate selected articles regarding our primary outcomes (Overall survival, Progression-free survival, death) and also our secondary outcomes (post embolization syndrome, hepatic abscesses, hepatic failure, gallbladder necrosis, non-target embolization). We will also search trial registries and the references of included studies to identify any additional published or unpublished studies for possible inclusion. Risk of bias will be assessed using the tools developed by Cochrane (i.e., the Cochrane RoB 2 tool for RCTs and cluster RCTs, and ROBINS-I for observational studies). We will conduct frequentists network meta-analyses, and we will use the Confidence in Network Meta-Analysis tool to assess the confidence in the evidence for the primary outcomes. Ethics and Dissemination We seek to publish our findings through peer review with a high impact, and readers will have access to the data gathered in this study. Because the underlying research is based on systematic evaluations of available data, it does not require approval by an ethical review board. The systematic review and meta-analysis’s findings will also be presented at various conferences and seminars. Strengths and Limitations This meta-analysis can be used to compare different types of intraarterial therapies for NELM, which can serve as a guide for choosing the best treatment option for non-surgical candidates. This research will lay the groundwork for future clinical trials comparing these therapy options, which can guide clinicians with a greater degree of certainty. Variations in specific therapy, like differences in medications used for intervention, may not be considered and may affect this comparison." @default.
• W4308733071 created "2022-11-15" @default.
• W4308733071 creator A5008176056 @default.
• W4308733071 creator A5008540039 @default.
• W4308733071 creator A5009205823 @default.
• W4308733071 creator A5013022915 @default.
• W4308733071 creator A5025801801 @default.
• W4308733071 creator A5039862332 @default.
• W4308733071 creator A5041483663 @default.
• W4308733071 creator A5074358617 @default.
• W4308733071 creator A5077022370 @default.
• W4308733071 creator A5080094799 @default.
• W4308733071 date "2022-11-07" @default.
• W4308733071 modified "2023-10-14" @default.
• W4308733071 title "Transarterial Therapy for Neuroendocrine Tumors: Protocol for a Systematic Review and Network Meta-analysis" @default.
• W4308733071 cites W1505768107 @default.
• W4308733071 cites W1896828031 @default.
• W4308733071 cites W1963519902 @default.
• W4308733071 cites W1964162160 @default.
• W4308733071 cites W1990509102 @default.
• W4308733071 cites W2036756589 @default.
• W4308733071 cites W2036782461 @default.
• W4308733071 cites W2037593179 @default.
• W4308733071 cites W2062011075 @default.
• W4308733071 cites W2065170253 @default.
• W4308733071 cites W2069999129 @default.
• W4308733071 cites W2074147400 @default.
• W4308733071 cites W2080299385 @default.
• W4308733071 cites W2083674804 @default.
• W4308733071 cites W2107457664 @default.
• W4308733071 cites W2116927325 @default.
• W4308733071 cites W2121594817 @default.
• W4308733071 cites W2121796373 @default.
• W4308733071 cites W2125435699 @default.
• W4308733071 cites W2161374186 @default.
• W4308733071 cites W2229261843 @default.
• W4308733071 cites W2531269403 @default.
• W4308733071 cites W2567362164 @default.
• W4308733071 cites W2575452307 @default.
• W4308733071 cites W2596664913 @default.
• W4308733071 cites W2608160487 @default.
• W4308733071 cites W2725873592 @default.
• W4308733071 cites W2966112907 @default.
• W4308733071 cites W2970684805 @default.
• W4308733071 cites W2975424845 @default.
• W4308733071 cites W2984757870 @default.
• W4308733071 cites W2988241563 @default.
• W4308733071 cites W3005532033 @default.
• W4308733071 cites W3011743134 @default.
• W4308733071 cites W3028489186 @default.
• W4308733071 cites W3088476737 @default.
• W4308733071 cites W3113033074 @default.
• W4308733071 cites W3118615836 @default.
• W4308733071 cites W3198989147 @default.
• W4308733071 doi "https://doi.org/10.1101/2022.11.06.22281733" @default.
• W4308733071 hasPublicationYear "2022" @default.
• W4308733071 type Work @default.
• W4308733071 citedByCount "0" @default.
• W4308733071 crossrefType "posted-content" @default.
• W4308733071 hasAuthorship W4308733071A5008176056 @default.
• W4308733071 hasAuthorship W4308733071A5008540039 @default.
• W4308733071 hasAuthorship W4308733071A5009205823 @default.
• W4308733071 hasAuthorship W4308733071A5013022915 @default.
• W4308733071 hasAuthorship W4308733071A5025801801 @default.
• W4308733071 hasAuthorship W4308733071A5039862332 @default.
• W4308733071 hasAuthorship W4308733071A5041483663 @default.
• W4308733071 hasAuthorship W4308733071A5074358617 @default.
• W4308733071 hasAuthorship W4308733071A5077022370 @default.
• W4308733071 hasAuthorship W4308733071A5080094799 @default.
• W4308733071 hasBestOaLocation W43087330711 @default.
• W4308733071 hasConcept C126322002 @default.
• W4308733071 hasConcept C126838900 @default.
• W4308733071 hasConcept C143998085 @default.
• W4308733071 hasConcept C168563851 @default.
• W4308733071 hasConcept C17744445 @default.
• W4308733071 hasConcept C199539241 @default.
• W4308733071 hasConcept C2776035437 @default.
• W4308733071 hasConcept C2776478404 @default.
• W4308733071 hasConcept C2779066768 @default.
• W4308733071 hasConcept C2779473830 @default.
• W4308733071 hasConcept C2909913126 @default.
• W4308733071 hasConcept C71924100 @default.
• W4308733071 hasConcept C95190672 @default.
• W4308733071 hasConceptScore W4308733071C126322002 @default.
• W4308733071 hasConceptScore W4308733071C126838900 @default.
• W4308733071 hasConceptScore W4308733071C143998085 @default.
• W4308733071 hasConceptScore W4308733071C168563851 @default.
• W4308733071 hasConceptScore W4308733071C17744445 @default.
• W4308733071 hasConceptScore W4308733071C199539241 @default.
• W4308733071 hasConceptScore W4308733071C2776035437 @default.
• W4308733071 hasConceptScore W4308733071C2776478404 @default.
• W4308733071 hasConceptScore W4308733071C2779066768 @default.
• W4308733071 hasConceptScore W4308733071C2779473830 @default.
• W4308733071 hasConceptScore W4308733071C2909913126 @default.
• W4308733071 hasConceptScore W4308733071C71924100 @default.
• W4308733071 hasConceptScore W4308733071C95190672 @default.
• W4308733071 hasLocation W43087330711 @default.
• W4308733071 hasOpenAccess W4308733071 @default.
• W4308733071 hasPrimaryLocation W43087330711 @default.
• W4308733071 hasRelatedWork W1967911880 @default.

• next